Consultoria estratègica especialitzada en Productes Sanitaris amb àmplia experiència en empreses amb integració vertical. Serveis en àreas de Qualitat (RA, QA, QC i Clinica)
L'objectiu es donar a coneixer l'empresa per ajudar a a start-ups i petites Pimes a conseguir els seus aobjectius de materialitzar una idea en un Producte Sanitari. Sempre amb qualitat, seguretat i plaços raonables
CCiTUB (Centres Científics i Tecnològics de la Universitat de Barcelona) is one of the largest mid-sized scientific and technical infrastructures in Spain, located at the Campus Diagonal of the University of Barcelona — the leading biotechnology hub in southern Europe.
With highly qualified technical staff and the widest variety of instrumental technologies in the country, CCiTUB offers specialised services to companies in the HealthTech sector with international quality standards, including ISO 9001:2015 certification.
Our key capabilities include:
Biomolecular Analysis: advanced proteomics, metabolomics, and small molecule ADME/PK studies
Pharmaceutical Characterisation: ultra-high-field NMR (1.0 GHz, unique in Spain) for biologics, antibodies, and nucleic acid fragments
Cell Analysis: multiparametric flow cytometry, immunophenotyping, and cell sorting for advanced therapies
Mass Spectrometry: hybrid Orbitrap IQ-X and QTRAP 7500 for metabolite identification, quality control, and biodistribution studies
Imaging: MALDI-Imaging, cryo-FIBSEM, and correlative microscopy for neurodegenerative disease research
CCiTUB serves pharma, biotech, diagnostics, medical devices, cosmetics, and nutraceutical sectors, providing immediate access to cutting-edge technologies without capital investment, backed by a network of over 100 health sector organisations and 2,700 professionals at the Barcelona Science Park.
CCiTUB seeks to connect with HealthTech companies looking for a reliable analytical partner to support their R&D and quality control needs. We are open to:
- Service agreements with pharma, biotech, diagnostics and medical device companies requiring advanced analytical capabilities
- Instrument evaluation partnerships with equipment manufacturers interested in testing and validating new instruments or applications, leveraging our expert technical team and broad network of over 2,700 researchers and professionals
- Public-private consortia for European and national research funding programmes (Horizon Europe, CDTI, etc.)
SCOPE is your experienced partner in clinical research. Since 2000, we have conducted over 300 studies in 30 countries, supporting all clinical phases (I–IV) and caring for more than 88,000 patients. We work closely with you to develop tailored solutions that streamline the process, allowing you to focus on what you do best. Let’s redefine pharmaceutical research together – get in touch today!
Sequentia Biotech is a Barcelona-based bioinformatics company founded in 2013. We transform omics data (genomics, transcriptomics, metagenomics, epigenomics) into actionable knowledge for clinical, industrial and research applications.
Maria Riba
Business Developer Iberia & LATAM
Partnership Goal
We are attending Connection Day 2026 to explore partnerships with:
Hospitals and clinical labs generating omics data that need advanced bioinformatic analysis to extract diagnostic or clinical value
Biopharma and medtech companies looking for a bioinformatics partner to support R&D pipelines, biomarker discovery, or precision medicine initiatives
Research centers and academic institutions interested in joining collaborative projects or European funding consortia where omics analysis is a key component
Health-tech startups with sequencing capabilities or omics datasets seeking analytical infrastructure and scientific expertise
If you work with biological data and need to turn it into clear, clinically or scientifically meaningful results, let's talk.
Synflora, is a biotech project, focusing on studying the human skin microbiome to enhance human health. The human body hosts trillions of microorganisms that interact closely with our cells. We regard the microbiome as an extension of the human host. By integrating its natural capabilities with innovative technologies based on proteins or active molecules, we aim to develop exclusive treatments for skin conditions and beyond.
We're looking for partner's to use our technology in producing cosmetics and investors in our platform solution of delivering therapeutics to the dermis